111, Inc. logo

111, Inc.

YI

NASDAQHealthcareMedical - Distribution

Previous close

$3.57

+$0.13 · +3.78%

Aug 21, 4:00 PM ET

YI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

35

Expensive

Momentum

26

Weakening

Sentiment

57

Mixed

Risk resilience

32

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
CN
CEO
Junling Liu
Listed since
Sep 12, 2018
Employees
1,063

Market position

Day range

Current $3.57

52-week range

Current $3.57

Open
$3.44
Previous close
$3.44
Volume
5.48K
0.3× average
Average volume
18.06K
Average daily volume
Market cap
31.19M USD
Beta
0.67
Market reference 1
50-day average
$3.9406
-9.40% below average
200-day average
$5.1383
-30.52% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-188.16M CNY
P/E (TTM)
-2.46×
P/B (TTM)
-1.97×
P/S (TTM)
0.02×
EV / EBITDA
-103.85×
Earnings yield
-10.81%
Free cash flow yield
73.63%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
5.74%
Operating margin
-0.24%
Net margin
-0.66%
Return on equity
2.40%
Return on assets
-0.77%
Return on invested capital
-2.31%

Financial health

Debt / equity
-0.38×
Current ratio
1.09×
Altman Z-score
37.97
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends7%3%-2%-7%Gross margin, FY2021: 5.00%Gross margin, FY2022: 6.21%Gross margin, FY2023: 5.68%Gross margin, FY2024: 5.76%Gross margin, FY2025: 5.76%Operating margin, FY2021: -5.17%Operating margin, FY2022: -2.74%Operating margin, FY2023: -2.34%Operating margin, FY2024: 0.01%Operating margin, FY2025: -0.08%Net margin, FY2021: -5.39%Net margin, FY2022: -3.08%Net margin, FY2023: -2.63%Net margin, FY2024: -0.45%Net margin, FY2025: -0.14%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 5.00%. Gross margin FY2022 6.21%. Gross margin FY2023 5.68%. Gross margin FY2024 5.76%. Gross margin FY2025 5.76%. Operating margin FY2021 -5.17%. Operating margin FY2022 -2.74%. Operating margin FY2023 -2.34%. Operating margin FY2024 0.01%. Operating margin FY2025 -0.08%. Net margin FY2021 -5.39%. Net margin FY2022 -3.08%. Net margin FY2023 -2.63%. Net margin FY2024 -0.45%. Net margin FY2025 -0.14%.

Income trends

Revenue

12.21B CNY-15.19%

Operating income

−10.03M CNY−12.14M CNY

Net income

−16.84M CNY+73.98%
Income trends across reported periods16.51B CNY10.26B CNY4.02B CNY−2.23B CNYRevenue, FY2021: 12.43B CNYRevenue, FY2022: 13.52B CNYRevenue, FY2023: 14.95B CNYRevenue, FY2024: 14.4B CNYRevenue, FY2025: 12.21B CNYOperating income, FY2021: −642.14M CNYOperating income, FY2022: −371M CNYOperating income, FY2023: −350.1M CNYOperating income, FY2024: 2.11M CNYOperating income, FY2025: −10.03M CNYNet income, FY2021: −669.81M CNYNet income, FY2022: −416.88M CNYNet income, FY2023: −392.69M CNYNet income, FY2024: −64.74M CNYNet income, FY2025: −16.84M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 12.43B CNY. Revenue FY2022 13.52B CNY. Revenue FY2023 14.95B CNY. Revenue FY2024 14.4B CNY. Revenue FY2025 12.21B CNY. Operating income FY2021 −642.14M CNY. Operating income FY2022 −371M CNY. Operating income FY2023 −350.1M CNY. Operating income FY2024 2.11M CNY. Operating income FY2025 −10.03M CNY. Net income FY2021 −669.81M CNY. Net income FY2022 −416.88M CNY. Net income FY2023 −392.69M CNY. Net income FY2024 −64.74M CNY. Net income FY2025 −16.84M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue12.21B CNY14.4B CNY14.95B CNY13.52B CNY12.43B CNY
Cost of goods sold11.51B CNY13.57B CNY14.1B CNY12.68B CNY11.8B CNY
Gross profit703.7M CNY829.23M CNY848.98M CNY839.98M CNY621.1M CNY
Selling, general, and administrative654.98M CNY384.8M CNY672.59M CNY663.5M CNY720.13M CNY
Operating expenses713.73M CNY827.12M CNY1.2B CNY1.21B CNY1.26B CNY
Interest income3.78M CNY7.04M CNY8.83M CNY8.12M CNY9.78M CNY
Interest expense34.6M CNY28.33M CNY20.14M CNY13.44M CNY5.49M CNY
Depreciation and amortization11.84M CNY16.97M CNY21.78M CNY40.82M CNY27.22M CNY
Operating income−10.03M CNY2.11M CNY−350.1M CNY−371M CNY−642.14M CNY
Net income−16.84M CNY−64.74M CNY−392.69M CNY−416.88M CNY−669.81M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.6

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.03-0.24-0.44-0.64Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q2 '26Q2 '26
Q3 2024, reported Aug 29, 2024: actual -0.2, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 27, 2024: actual -0.282, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 20, 2025: actual -0.04, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 19, 2025: actual -0.276, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 17, 2025: actual -0.312, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Dec 17, 2025: actual -0.2, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Apr 9, 2026: actual -0.257, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Jun 4, 2026: actual -0.6, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates623.56M521.8M420.04M318.28MQ3 '24MissQ4 '24MissQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ2 '26MissQ2 '26No estimate
Q3 2024, reported Aug 29, 2024: actual 471.06M USD, estimate 478.3M USD, surprise -1.51%, Miss. Q4 2024, reported Nov 27, 2024: actual 512.95M USD, estimate 518.84M USD, surprise -1.13%, Miss. Q1 2025, reported Mar 20, 2025: actual 526.99M USD, estimate 542.09M USD, surprise -2.78%, Miss. Q2 2025, reported Jun 19, 2025: actual 486.19M USD, estimate 529.83M USD, surprise -8.24%, Miss. Q3 2025, reported Sep 17, 2025: actual 447.36M USD, estimate 520.94M USD, surprise -14.12%, Miss. Q4 2025, reported Dec 17, 2025: actual 421.41M USD, estimate 551.19M USD, surprise -23.55%, Miss. Q2 2026, reported Apr 9, 2026: actual 403.17M USD, estimate 599.57M USD, surprise -32.76%, Miss. Q2 2026, reported Jun 4, 2026: actual 342.26M USD, estimate —, surprise —, Comparison unavailable.

YI news

YI peers

Continue in GoAI

Research YI

research.disclaimer